Aratana Announces Positive Results From Pilot Field Study Of AT-002 In Cats

(RTTNews) - Aratana Therapeutics, Inc. (PETX), a pet therapeutics company, announced the positive results of a pilot field study of AT-002 (capromorelin) in cats.

Capromorelin is a small molecule that mimics ghrelin, the naturally occurring hormone that stimulates appetite, increases body weight and increases serum growth hormone levels.

The multi-site, placebo-controlled, pilot field study of approximately 40 cats measured weight gain/loss in cats with chronic kidney disease and documented weight loss who received AT-002 at a dose of 2 mg/kg compared to cats that received placebo treatment.

Both groups were treated orally once daily for 90±3 days. AT-002 treated cats had statistically significant increases in body weight compared to placebo after 90 days.